Experimental drug shows promise in rare melanoma subtype
NCT ID NCT02975700
First seen Jan 21, 2026 · Last updated May 10, 2026 · Updated 14 times
Summary
This study tested an experimental drug called PLX3397 in 6 people with advanced melanoma that has a specific change in the KIT gene. The goal was to see if the drug is safe and can shrink tumors. While some patients had their tumors shrink or stay stable, the study was very small and more research is needed.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MELANOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Beijing Cancer Hospital
Beijing, Beijing Municipality, 100142, China
-
Samsung Medical Center
Seoul, Gangnam-Gu, 06351, South Korea
-
Seoul National University Hospital
Seoul, South Korea
-
Severance Hospital, Yonsei University Health System
Seoul, Seodaemun-gu, 03722, South Korea
-
Sun Yat-sen Hospital
Guangzhou, Guangdong, China
Conditions
Explore the condition pages connected to this study.